Wave Life Sciences Ltd.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul Bolno
- Full Time Employees
- 317
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 733 Concord Avenue Cambridge MA United States of America 02138
- IPO Date
- Nov 11, 2015
- CIK
- 0001631574
- Website
- wavelifesciences.com
- Similar Companies
- Business
- Wave Life Sciences Ltd. (Nasdaq: WVE) is a clinical-stage biotechnology company that designs, develops and commercializes stereopure ribonucleic acid (RNA) medicines for genetically defined diseases utilizing its proprietary PRISM platform; the platform combines multiple RNA-targeting modalities including RNA editing via AIMer technology, antisense silencing, and RNA interference with chemistry innovation and human genetics insights to create differentiated therapeutics. Core programs target alpha-1 antitrypsin deficiency (AATD) with WVE-006, a GalNAc-conjugated RNA editing oligonucleotide licensed exclusively to GSK; obesity with WVE-007, a GalNAc-siRNA targeting INHBE that demonstrated up to 85% Activin E reductions in the INLIGHT trial supporting potential once- or twice-yearly dosing for fat loss and muscle preservation; Duchenne muscular dystrophy (DMD) with WVE-N531, an exon-skipping oligonucleotide advancing toward a 2026 New Drug Application filing; and Huntington's disease (HD) with WVE-003, which received supportive FDA feedback including orphan drug designation. The company operates primarily in the genetic medicines industry serving patients with rare and prevalent disorders such as AATD, DMD, HD and obesity through wholly owned and partnered programs. Founded in 2012 and headquartered in Singapore with key research and development operations in Cambridge, Massachusetts, Wave maintains a UK subsidiary focused on pharmaceutical manufacturing. Recent developments include positive third-quarter 2025 clinical data for WVE-007 and WVE-006 validating RNA editing and RNAi capabilities; GSK's acquisition of additional shares worth $22.3 million in September 2024 increasing its ownership; termination of the Takeda collaboration in October 2024 allowing Wave to regain full control of its HD program; preclinical advancements supporting WVE-007 as monotherapy, GLP-1 add-on or maintenance therapy; and a cash position extending runway into 2027.
Company News
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences to Present at Upcoming Investor Conferences
WAVE Life Sciences Q2 Earnings Call Highlights
Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
New Strong Buy Stocks for July 22nd
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wave Life Sciences to Present at Upcoming Investor Conferences